Guerreiro Mara Pereira, Cantrill Judith A, Martins Ana Paula
School of Pharmacy & Pharmaceutical Sciences, University of Manchester, United Kingdom.
Acta Med Port. 2007 Mar-Apr;20(2):107-29. Epub 2007 Jun 11.
Preventable drug-related morbidity (PDRM) indicators are operational measures of therapeutic risk management. These clinical indicators, which cover a wide range of drugs, combine process and outcome in the same instrument. They were developed in the US and have been validated for primary care settings in the US, UK and Canada. This study is part of a research programme; it aimed to determine a valid set of PDRM indicators for adult patients in primary care in Portugal. Face validity of 61 US and UK-derived indicators translated to Portuguese was preliminarily determined by means of a postal questionnaire using a purposive sample of four Portuguese pharmacists with different backgrounds. Preliminary content validity of indicators approved in the previous stage was determined by cross-checking each definition of PDRM with standard drug information sources in Portugal. Face and content validity of indicators yielded by preliminary work were then established by a 37 expert panel (20 community pharmacists and 17 general practitioners) using a two-round Delphi survey. Data were analysed using SPSS release 11.5. Nineteen indicators were ruled out in preliminary validation. Changes were made in the content of eight of the remaining 42 indicators; these were related to differences in the drugs being marketed and patterns of drug monitoring between countries. Thirty-five indicators were consensus approved as PDRM for adult patients in Portuguese primary care by the Delphi panel.
可预防的药物相关发病率(PDRM)指标是治疗风险管理的操作性措施。这些临床指标涵盖多种药物,在同一工具中结合了过程和结果。它们在美国开发,并已在美国、英国和加拿大的初级保健环境中得到验证。本研究是一项研究计划的一部分;其目的是为葡萄牙初级保健中的成年患者确定一套有效的PDRM指标。通过对四名背景不同的葡萄牙药剂师进行有目的抽样,利用邮政问卷初步确定了61项从美国和英国衍生并翻译成葡萄牙语的指标的表面效度。通过将PDRM的每个定义与葡萄牙的标准药物信息来源进行交叉核对,确定了前一阶段批准的指标的初步内容效度。然后,由一个37人组成的专家小组(20名社区药剂师和17名全科医生)通过两轮德尔菲调查确定了初步工作产生的指标的表面效度和内容效度。使用SPSS 11.5版对数据进行分析。在初步验证中排除了19项指标。其余42项指标中的8项在内容上进行了修改;这些修改与各国正在销售的药物差异和药物监测模式有关。德尔菲小组一致批准了35项指标作为葡萄牙初级保健中成年患者的PDRM指标。